7 results about "Intracellular signaling pathways" patented technology

Provided are an anti-ST2 antibody or a fragment thereof. The antibody or the fragment thereof can be specifically bound to human ST2, for inhibiting combination of IL-33 and human ST2, blocking an IL-33 / ST2 intracellular signaling pathway, and inhibiting the promoting effect of different forms of IL-33 in cell-derived IL5, IL6 and 118 production. Compared with a known anti-ST2 antibody, this anti-ST2 antibody has higher biological activity, and can be used for preventing, treating or alleviating diseases related to ST2 expression or IL-33 / ST2 pathway disorders.

The present invention relates to the field of cell therapy. Disclosed are a fibroblast activation protein-targeting CAR T-cell, a preparation method therefor, and an application thereof. A CAR T-cell can be prepared by introducing an FAP-targeting chimeric antigen receptor (CAR) into a T lymphocyte, wherein the CAR in the CAR T-cell comprises a signal peptide, an antigen-binding domain, a hinge region, a transmembrane domain, a co-stimulatory signaling region, and a CD3 signaling domain. The CAR T-cell specifically recognizes the FAP by means of a single-chain variable fragment (scFv), which activates an intracellular signaling pathway, releasing cytokine IFN-γ, and exhibiting a cytotoxic effect on FAP+ cells, thereby achieving specific depletion of FAP+ cells at a lesion site. The CAR-T cell can be used for treating diseases characterized by upregulated FAP expression, such as fibrosis (pulmonary fibrosis, hepatic fibrosis, cardiac fibrosis, renal fibrosis, etc.), arthritis, autoimmune disorders (Crohn's disease, rheumatoid arthritis, etc.), and cardiovascular diseases, and demonstrates tremendous application potential and commercial value.

The invention discloses an application of a PROTAC-HDAC7 compound in preparation of a medicine for preventing and treating acute kidney injury, and belongs to the technical field of biological medicines, and the acute kidney injury is caused by one or more of cisplatin, lipopolysaccharide (LPS) and H / R. The PROTAC-HDAC7 compound disclosed by the invention has the beneficial effects that the PROTAC-HDAC7 compound is used for preventing and treating the acute kidney injury by reducing the levels of KIM1, MCP-1, IL-6 and TNF-alpha, and signal paths related to the acute kidney injury in cells can be more effectively regulated by inducing degradation of HDAC7 instead of only inhibiting the activity of the HDAC7.

This invention discloses a chitosan-based lidocaine formulation for intra-articular use and its preparation method. Belonging to the field of pharmaceutical formulation technology, the formulation is prepared from chitosan, carboxymethyl chitosan, lidocaine, chitosan-PNIPAM microspheres, sulfated trehalose, and excipients. The chitosan-PNIPAM used in this invention exhibits dual temperature and pH response. With temperature changes, PNIPAM possesses both hydrophobic contractile and hydrophilic swelling states, thereby controlling the lidocaine release rate. Simultaneously, when the pH decreases, chitosan repels PNIPAM, further disintegrating the microspheres to release the drug, thus achieving targeted analgesia. Sulfated trehalose, as a cartilage matrix synthesis promoter, can activate intracellular signaling pathways in chondrocytes, promoting the synthesis of type II collagen and proteoglycans. Simultaneously, the sulfate groups can form electrostatic complexes with the amino groups of chitosan, enhancing drug retention. The formulation of this invention can inhibit synovial cells, release cytokines, and synergistically with carboxymethyl chitosan, increase the inhibition rate of inflammatory factors by 40%-50%.

This invention relates to the technology of antibodies, and more specifically, to antibodies that bind to the IL-18 receptor, IL-18 receptor activators, and their use. The invention provides antibodies that specifically bind to IL-18R1 and IL-18RAP with high affinity, and further provides bispecific antibodies that can efficiently bind both IL-18R1 and IL-18RAP simultaneously. These bispecific antibodies are novel IL-18 receptor activators that can activate the intracellular signaling pathway mediated by IL-18R1 / IL-18RAP, exert biological functions similar to IL-18 both in vitro and in vivo, and possess broad immunostimulatory effects and remarkable antitumor activity. Furthermore, they possess controllable activating activity, excellent molecular stability, and in vivo pharmacokinetic characteristics, which are advantageous for fully exhibiting antitumor efficacy in vivo, and offer prospects for a wide range of antitumor clinical applications.

This invention relates to the field of single-cell functional analysis and microfluidic chip technology, and discloses a kit and method for in-situ sequential quantitative detection of secreted and intracellular proteins in the same single cell. The kit includes: a microcavity array chip; a secreted protein capture antibody barcode chip and an intracellular protein capture antibody barcode chip; a plastic clamp; a bioaffinity modification reagent; secreted protein standards, intracellular protein standards, secreted protein detection antibody stock solution, and intracellular protein detection antibody stock solution; a fluorescent conjugate, antibody buffer, antibody blocking solution, cell lysis buffer, and cell washing buffer. The method of this invention, through a sequential detection process of first capturing and incubating secreted proteins, followed by in-situ lysis to capture intracellular proteins, achieves high-throughput, high-sensitivity, and high-specificity in-situ sequential quantitative detection of secreted and intracellular proteins in the same single cell without cell transfer or loss of spatial location information. It can establish a correlation analysis of "intracellular signaling pathway activation - external functional output" in single cells, providing a powerful tool for disease mechanism research, drug screening, and immunotherapy evaluation.

Provided herein are small molecule modulators of RXFP1, and methods of making and use thereof. These compounds are pharmacological mimetics of relaxin H2 signaling and are capable of activating RXFP1. This activation triggers intracellular signaling pathways that mediate physiological functions in many tissues, including the reproductive, cardiovascular, renal, hepatic, and connective tissues. As such, these compounds are useful in the treatment of a variety of indications, including heart failure and other RXFP1 related diseases in patients in need thereof.